SPTX News & Events

Seaport Therapeutics priced 14.2M shares at $18.00. The deal size was increased to 14.2M shares of common stock from 11.8M shares and priced at the high-end of the $16.00-$18.00 range. Goldman Sachs, JPMorgan, Leerink, Citi and Stifel acted as joint book running managers for the offering. Seaport Therapeutics is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other neuropsychiatric disorders.

The deal size was increased to 14.2M shares of common stock from 11.8M shares of common stock and priced at the high-end of the $16.00-$18.00 range. Goldman Sachs, JPMorgan, Leerink, Citi and Stifel acted as joint book running managers for the offering.